Stemline Drug Patent Portfolio
Stemline owns 1 orange book drug protected by 8 US patents Given below is the list of Stemline's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10385008 | Polymorphic forms of RAD1901-2HCL | 05 Jan, 2038 | Active |
| US10745343 | Polymorphic forms of RAD1901-2HCl | 05 Jan, 2038 | Active |
| US11819480 | Methods for treating cancer | 28 Feb, 2037 | Active |
| US10420734 | Method of treating cancer using selective estrogen receptor modulators | 03 Oct, 2036 | Active |
| US10071066 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
| US11779552 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
| US7612114 | Selective estrogen receptor modulator | 18 Aug, 2026 | Active |
| US8399520 | Selective estrogen receptor modulator | 25 Dec, 2025 | Expired |
Latest Legal Activities on Stemline's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Stemline.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Withdrawal of Application for PTE | 28 Aug, 2025 | US10071066 |
| Withdrawal of Application for PTE | 28 Aug, 2025 | US7612114 |
| Withdrawal of Application for PTE | 28 Aug, 2025 | US8399520 |
| Election in Response to Notice of Final Determination | 08 Aug, 2025 | US8399520 |
| Election in Response to Notice of Final Determination | 08 Aug, 2025 | US7612114 |
| Election in Response to Notice of Final Determination | 07 Aug, 2025 | US10071066 |
| Notice of Final Determination -Election Required | 09 Jul, 2025 | US10071066 |
| Notice of Final Determination -Election Required | 09 Jul, 2025 | US7612114 |
| Notice of Final Determination -Election Required | 09 Jul, 2025 | US8399520 |
| Notice of Final Determination -Election Required | 09 Jul, 2025 | US10420734 |
| Mail Patent eCofC Notification | 01 Jul, 2025 | US11819480 |
| Email Notification | 01 Jul, 2025 | US11819480 |
| Patent eCofC Notification | 01 Jul, 2025 | US11819480 |
| Recordation of Patent eCertificate of Correction | 01 Jul, 2025 | US11819480 |
| Post Issue Communication - Certificate of Correction | 12 Jun, 2025 | US11819480 |
Stemline's Family Patents
Stemline drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 41.5% of its total global patent coverage. Click
below to unlock the full patent family tree.
Stemline Drug List
Given below is the complete list of Stemline's drugs and the patents protecting them.
1. Orserdu
Orserdu is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10385008 | Polymorphic forms of RAD1901-2HCL |
05 Jan, 2038
(11 years from now)
| Active |
| US10745343 | Polymorphic forms of RAD1901-2HCl |
05 Jan, 2038
(11 years from now)
| Active |
| US11819480 | Methods for treating cancer |
28 Feb, 2037
(10 years from now)
| Active |
| US10420734 | Method of treating cancer using selective estrogen receptor modulators |
03 Oct, 2036
(10 years from now)
| Active |
| US10071066 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(8 years from now)
| Active |
| US11779552 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(8 years from now)
| Active |
| US7612114 | Selective estrogen receptor modulator |
18 Aug, 2026
(5 months from now)
| Active |
| US8399520 | Selective estrogen receptor modulator |
25 Dec, 2025
(2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orserdu's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List